Liposome Drug Delivery Market Share

North American Market Forecast

North America industry is anticipated to dominate majority revenue share of 45% by 2037. The growth of the market in the region can primarily be attributed to the increasing prevalence of cancer in the region, followed by the surge in government initiatives that promote research and development for cancer drugs and drug delivery systems. According to the statistics by the National Cancer Institute (NCI), in the year 2020, the new cases of cancer that were expected to be diagnosed in the United States were about 1806590 cases. The statistics also stated that during the same year, 606520 people were expected to die as a result of the disease.

Europe Market Forecast

On the other hand, the liposome drug delivery market in Europe is projected to garner the second-largest revenue of 31% by the end of 2036. The market in Germany is projected to garner the second-largest revenue by the end of 2036 in Europe. The growing incidence of chronic illnesses including cancer and cardiovascular disease is driving the market. The rising demand for personalized medicine and the need for improved drug efficacy and safety are driving market growth.  The market for liposome delivery in Europe is highly regulated with stringent safety and efficacy guidelines. Companies operating in the market must comply with these regulations to obtain approval for their products.